Mumbai (MMR)
Home / Diagnostics Test / Lung Panel – 2
L0060
Lung Panel – 2
Number of Tests 6
Test Included EGFR Sequencing, ALK, ROS
Test Details: Activating mutations in EGFR are present in approximately 10-12% of Non small cell lung carcinoma (NSCLC), most of which predict a good response to treatment with EGFR inhibitors such as gefitinib and erlotinib. Exceptions are insertion mutations in exon 20 and the T790M substitution, which confer resistance to these drugs. ALK gene rearrangements are present in approximately 5% of NSCLC, the most common being EML4-ALK fusion. Activation of ALK kinase through these gene fusions can be inhibited by ALK inhibitors such as crizotinib. Gene fusions involving ROS1 are present in 1-2% of NSCLC. ROS1 gene fusions activate ROS kinase which is sensitive to crizotinib.
Category
Molecular Genetics + Cytogenetics
Pre-test Information
H & E report, grossing details, duration of fixation, clinical details and site of lesion / biopsy is required.
Report Delivery
5 working days
Gender
All
Organ
Lung
Lung Panel – 2
13000
Most Searched Diagnostic Tests
H0192
17 Hydroxy Corticosteroids Urine
Report Delivery: 3 working days
3800
View Details
K0015
17 Ketosteroids Urine
Report Delivery: 3 working days
3800
View Details
P0144
17 OH Progesterone
Report Delivery: 1 working day
1300
View Details